
Cost, route of administration, tolerability, and care team experience all shape adoption, while anticipated approvals of oral options point toward a more crowded first-line landscape.

Cost, route of administration, tolerability, and care team experience all shape adoption, while anticipated approvals of oral options point toward a more crowded first-line landscape.

Patient preference for oral therapy, early CNS penetration data, and both positive and negative phase 3 readouts are shaping how clinicians may sequence exon 20-targeted agents.

With three first-line strategies emerging, differences in toxicity and CNS activity may matter as much as efficacy, while final survival results reinforce the value of the established combination.

A phase 3 trial of an exon 20-specific oral inhibitor combined with chemotherapy reports improved progression-free survival and response, alongside cytopenias concentrated in the induction phase.

Clinic-based administration, toxicity management, and frequent CNS involvement all add to the burden of this disease, sharpening interest in oral inhibitors built specifically for exon 20 insertions.

Efficacy sets the starting point, but performance status, comorbidities, patient priorities, and distinct adverse event patterns determine which first-line regimen a patient actually receives.

A rare EGFR subtype demands comprehensive molecular testing at diagnosis, and the first-line standard has shifted from chemotherapy alone to a targeted combination with survival benefit.